CD47-mediated efferocytosis in diseases: A comprehensive review.

Congcong Wang, Shidi Yu, Jiayu Kang, Shuhang Yang, Zhenhao Pan, Yu Zhao, Chunjiang Li, Wei Zhu

Abstract readReview

In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Congcong WangDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Shidi YuDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Jiayu KangDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Shuhang YangDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Zhenhao PanDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Yu ZhaoDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China.

Chunjiang LiDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China. Lichunjiang0526@163.com.

Wei ZhuDepartment of Immunology, Mudanjiang Medical University, No. 3, Tongxiang Street, Mudanjiang, 157011, Heilongjiang, China. zhuzwwei@163.com.ORCID https://orcid.org/0000-0001-5998-5834

Funding

Innovative Team Project of Mudanjiang Medical University 2022-MYHJ-002Key Project of the Natural Science Joint Fund of Heilongjiang Province ZL2025H013

6 · The paper itself

Abstract

Efferocytosis is a vital process by which phagocytes, such as macrophages, recognize and clear apoptotic cells, making it essential for maintaining tissue homeostasis and promoting the resolution of inflammation. Impaired efferocytosis can lead to the secondary necrosis of apoptotic cells and the continuous release of inflammatory factors, thereby contributing to the occurrence and development of various diseases, including tumors, atherosclerosis (AS), autoimmune diseases, and neurodegenerative diseases. CD47, a transmembrane glycoprotein widely expressed on the cell surface, binds to signal regulatory protein α (SIRPα) on the macrophage surface to transmit the classic "don't eat me" signal, which negatively regulates the efferocytic process. Under pathological conditions, abnormally high CD47 expression helps abnormal cells evade immune clearance; as a result, the CD47/SIRPα axis has gradually become an important immune checkpoint in the regulation of efferocytosis. Focusing on CD47-mediated efferocytosis, this paper reviews its molecular mechanisms and recent research progress in diseases like tumors and AS, with the aim of providing new insights for the immunotherapy and clinical translation of related disorders.

Indexed as

CD47 AntigenEfferocytosisAnimalsAntigens, DifferentiationApoptosisAtherosclerosisAutoimmune DiseasesHumansInflammationMacrophagesNeoplasmsPhagocytosisReceptors, ImmunologicSignal TransductionAntigens, DifferentiationCD47 AntigenCD47 protein, humanReceptors, ImmunologicSIRPA protein, humanCD47EfferocytosisImmune regulationMacrophages

Identifiers

PMID42804006

DOI10.1016/j.tranon.2021.101129

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.